Bisphosphonamidate clodronate prodrug exhibits potent anticancer activity in non-small-cell lung cancer cells

Marie R. Webster, Ming Zhao, Michelle Rudek-Renaut, Christine Hann, Caren L Meyers

Research output: Contribution to journalArticle

Abstract

Bisphoshonates are used clinically to treat disorders of calcium metabolism, hypercalcemia and osteoporosis, and malignant bone disease. Although these agents are commonly used in cancer patients and have potential direct anticancer effects, their use for the treatment of extraskeletal disease is limited as a result of poor cellular uptake. We have designed and synthesized bisphosphonamidate prodrugs that undergo intracellular activation to release the corresponding bisphosphonate and require only two enzymatic activation events to unmask multiple negative charges. We demonstrate efficient bisphosphonamidate activation and significant enhancement in anticancer activity of two bisphosphonamidate prodrugs in vitro compared to the parent bisphosphonate. These data suggest a novel approach to optimizing the anticancer activities of commonly used bisphosphonates.

Original languageEnglish (US)
Pages (from-to)6647-6656
Number of pages10
JournalJournal of Medicinal Chemistry
Volume54
Issue number19
DOIs
StatePublished - Oct 13 2011

Fingerprint

Clodronic Acid
Prodrugs
Diphosphonates
Non-Small Cell Lung Carcinoma
Calcium Metabolism Disorders
Bone Diseases
Hypercalcemia
Osteoporosis
Neoplasms
Therapeutics

ASJC Scopus subject areas

  • Molecular Medicine
  • Drug Discovery

Cite this

Bisphosphonamidate clodronate prodrug exhibits potent anticancer activity in non-small-cell lung cancer cells. / Webster, Marie R.; Zhao, Ming; Rudek-Renaut, Michelle; Hann, Christine; Meyers, Caren L.

In: Journal of Medicinal Chemistry, Vol. 54, No. 19, 13.10.2011, p. 6647-6656.

Research output: Contribution to journalArticle

@article{8301e9a485b042108a7ac0d95a15b5dc,
title = "Bisphosphonamidate clodronate prodrug exhibits potent anticancer activity in non-small-cell lung cancer cells",
abstract = "Bisphoshonates are used clinically to treat disorders of calcium metabolism, hypercalcemia and osteoporosis, and malignant bone disease. Although these agents are commonly used in cancer patients and have potential direct anticancer effects, their use for the treatment of extraskeletal disease is limited as a result of poor cellular uptake. We have designed and synthesized bisphosphonamidate prodrugs that undergo intracellular activation to release the corresponding bisphosphonate and require only two enzymatic activation events to unmask multiple negative charges. We demonstrate efficient bisphosphonamidate activation and significant enhancement in anticancer activity of two bisphosphonamidate prodrugs in vitro compared to the parent bisphosphonate. These data suggest a novel approach to optimizing the anticancer activities of commonly used bisphosphonates.",
author = "Webster, {Marie R.} and Ming Zhao and Michelle Rudek-Renaut and Christine Hann and Meyers, {Caren L}",
year = "2011",
month = "10",
day = "13",
doi = "10.1021/jm200521a",
language = "English (US)",
volume = "54",
pages = "6647--6656",
journal = "Journal of Medicinal Chemistry",
issn = "0022-2623",
publisher = "American Chemical Society",
number = "19",

}

TY - JOUR

T1 - Bisphosphonamidate clodronate prodrug exhibits potent anticancer activity in non-small-cell lung cancer cells

AU - Webster, Marie R.

AU - Zhao, Ming

AU - Rudek-Renaut, Michelle

AU - Hann, Christine

AU - Meyers, Caren L

PY - 2011/10/13

Y1 - 2011/10/13

N2 - Bisphoshonates are used clinically to treat disorders of calcium metabolism, hypercalcemia and osteoporosis, and malignant bone disease. Although these agents are commonly used in cancer patients and have potential direct anticancer effects, their use for the treatment of extraskeletal disease is limited as a result of poor cellular uptake. We have designed and synthesized bisphosphonamidate prodrugs that undergo intracellular activation to release the corresponding bisphosphonate and require only two enzymatic activation events to unmask multiple negative charges. We demonstrate efficient bisphosphonamidate activation and significant enhancement in anticancer activity of two bisphosphonamidate prodrugs in vitro compared to the parent bisphosphonate. These data suggest a novel approach to optimizing the anticancer activities of commonly used bisphosphonates.

AB - Bisphoshonates are used clinically to treat disorders of calcium metabolism, hypercalcemia and osteoporosis, and malignant bone disease. Although these agents are commonly used in cancer patients and have potential direct anticancer effects, their use for the treatment of extraskeletal disease is limited as a result of poor cellular uptake. We have designed and synthesized bisphosphonamidate prodrugs that undergo intracellular activation to release the corresponding bisphosphonate and require only two enzymatic activation events to unmask multiple negative charges. We demonstrate efficient bisphosphonamidate activation and significant enhancement in anticancer activity of two bisphosphonamidate prodrugs in vitro compared to the parent bisphosphonate. These data suggest a novel approach to optimizing the anticancer activities of commonly used bisphosphonates.

UR - http://www.scopus.com/inward/record.url?scp=80053898529&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053898529&partnerID=8YFLogxK

U2 - 10.1021/jm200521a

DO - 10.1021/jm200521a

M3 - Article

VL - 54

SP - 6647

EP - 6656

JO - Journal of Medicinal Chemistry

JF - Journal of Medicinal Chemistry

SN - 0022-2623

IS - 19

ER -